An observational study in Multiple Sclerosis and Hearing Disorders, sponsored by University of Catania. Recruiting at 1 site in Italy. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by University of Catania · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 289 studies in Multiple Sclerosis with a site in Italy — 59 open to participants now, 90 under way, 13 of them phase 3. Multiple Sclerosis · Italy.
Among the 289 studies in Multiple Sclerosis with a site in Italy, this one is the 56th largest by planned enrollment of the 59 observational ones that give a count, is one of 11 that started in 2026, is one of 59 observational ones, reaches primary completion later than 73 of the 89 other live ones, and was the 232nd registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →59 of the 289 studies in Multiple Sclerosis with a site in Italy are open now. Recruiting first, the newest first:
Ciceri Fabio · Sites in Italy
Ages 18+
Azienda Usl di Bologna · Sites in Italy
Ages 18–65
Sanofi · Sites in Italy, United States, Belgium and 4 more countries
Ages 18–60
Novartis Pharmaceuticals · Sites in Italy, United States, Argentina and 33 more countries
Ages 18–65
Hasselt University · Sites in Italy, Belgium, Spain
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 20 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
289 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 40 · Phase 3 66 · Phase 4 19
First in 1999; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 115 across the 230 interventional studies, 214 across the 59 observational. Of the 164 that completed or were terminated, 77 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 289 have an industry lead sponsor. The 10 most frequent:
University of Catania is the lead sponsor of 71 studies on the registry; 15 are open to participants now.
University of Catania has 2 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
17 of the studies in Multiple Sclerosis with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
| NCT05748015Istituti Clinici Scientifici Maugeri SpADefinition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis | 2026-11-30 |
| NCT07502066IRCCS San Camillo, Venezia, ItalyClinical Efficacy of a telerehabilItation Protocol, for the Improvement of Balance in Degenerative Neurological Diseases | 2026-12 |
| NCT07616050Marta MondelliniEvaluation of the Impact of Virtual Park on Training Motivation in Adult Patients | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 289 studies in Multiple Sclerosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will analyze the auditory functions of patients with Multiple Sclerosis using auditory tests like pure tone auditory test, speech perception test, Auditory Brain Response (ABR) and Distortion Product Otoacustic Emission (DPOAE). CSF will be collected by lumbar puncture and analyzed looking for inflammatory markers.
The results of DPOAE and CSF will be correlated to identify statistically significant correlation.
Case-Control study
Tools for patients' selection and inclusion in the study
STEP one
STEP two
STEP three in case of Hearing impairment
- MRI Tractography
Healthy patients and patients with RRMS
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Healthy patients between 20 and 40 years
Diagnostic Test: Auditory test · Other: CSF sampling
Patient with Relapsing Remitting MS age between 20 and 40 years
Diagnostic Test: Auditory test · Other: CSF sampling
The patients will perform: Pure Tone Auditory test + Tympanometry and Stapedial Reflex * Speech Perception test * In case of tinnitus: tinnitus questionnaire and acuphenometry * DPOAEs * ABR
Cerebrospinal Fluid will be collected by lumbar puncture and analyzed
Auditory functions and correlation with CSF findings
The worsening of the hearing thresholds and DPOAE results will be correlated with the presence of inflammatory elements in the CSF
Time frame: 12 months
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan
Time frame: 24 months for 12 months
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Dec 2027, 19 months after the start.
Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's planned 19 months is below that.
Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Catania